Skip to main content

Table 2 The primary and secondary endpoints of two groups

From: Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients

Endpoints

Genotype-guided group (n = 99)

Non-genotype-guided group (n = 102)

HR(95%CI)

p-Value

The primary endpoints (a composite of stroke and myocardial infarction)

13(13.1%)

30(29.4%)

0.39(0.20–0.75)

0.004

The secondary end points

 Recurrent stroke

12(12.1%)

28(27.5%)

0.39(0.20–0.76)

0.006

 Ischemic stroke

11(11.1%)

26(25.4%)

0.38(0.19–0.77)

0.007

 Hemorrhagic stroke

1(1.0%)

2(2.0%)

0.44(0.04–4.88)

0.505

Myocardial infarction

1(1.0%)

2(2.0%)

0.45(0.04–4.92)

0.509

All-cause mortality

3(3.0%)

8(7.8%)

0.34(0.09–1.29)

0.114